350 related articles for article (PubMed ID: 33922083)
21. Lymphangioleiomyomatosis - a wolf in sheep's clothing.
Henske EP; McCormack FX
J Clin Invest; 2012 Nov; 122(11):3807-16. PubMed ID: 23114603
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
Himes BE; Obraztsova K; Lian L; Shumyatcher M; Rue R; Atochina-Vasserman EN; Hur SK; Bartolomei MS; Evans JF; Krymskaya VP
PLoS One; 2018; 13(5):e0197105. PubMed ID: 29758070
[TBL] [Abstract][Full Text] [Related]
23. Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis.
Marsh KM; Schipper D; Ferng AS; Johnson K; Fisher J; Knapp S; Dicken D; Khalpey Z
Lung; 2017 Aug; 195(4):425-430. PubMed ID: 28577037
[TBL] [Abstract][Full Text] [Related]
24. [Lymphangioleiomyomatosis].
Wirtz H
Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
[TBL] [Abstract][Full Text] [Related]
25. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
26. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis.
Harari S; Spagnolo P; Cocconcelli E; Luisi F; Cottin V
Curr Opin Pulm Med; 2018 Sep; 24(5):469-476. PubMed ID: 29927757
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
30. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
31. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
[TBL] [Abstract][Full Text] [Related]
32. Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.
Ruiz de Garibay G; Herranz C; Llorente A; Boni J; Serra-Musach J; Mateo F; Aguilar H; Gómez-Baldó L; Petit A; Vidal A; Climent F; Hernández-Losa J; Cordero Á; González-Suárez E; Sánchez-Mut JV; Esteller M; Llatjós R; Varela M; López JI; García N; Extremera AI; Gumà A; Ortega R; Plà MJ; Fernández A; Pernas S; Falo C; Morilla I; Campos M; Gil M; Román A; Molina-Molina M; Ussetti P; Laporta R; Valenzuela C; Ancochea J; Xaubet A; Casanova Á; Pujana MA
PLoS One; 2015; 10(7):e0132546. PubMed ID: 26167915
[TBL] [Abstract][Full Text] [Related]
33. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Chebib N; Archer F; Bobet-Erny A; Leroux C; Cottin V
Sci Rep; 2018 Oct; 8(1):14698. PubMed ID: 30279475
[TBL] [Abstract][Full Text] [Related]
36. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
37. Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells.
Olatoke T; Wagner A; Astrinidis A; Zhang EY; Guo M; Zhang AG; Mattam U; Kopras EJ; Gupta N; Smith EP; Karbowniczek M; Markiewski MM; Wikenheiser-Brokamp KA; Whitsett JA; McCormack FX; Xu Y; Yu JJ
Sci Adv; 2023 May; 9(19):eadf8549. PubMed ID: 37163604
[TBL] [Abstract][Full Text] [Related]
38. Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis.
Adachi K; Miki Y; Saito R; Hata S; Yamauchi M; Mikami Y; Okada Y; Seyama K; Kondo T; Sasano H
Hum Pathol; 2015 Nov; 46(11):1685-93. PubMed ID: 26298231
[TBL] [Abstract][Full Text] [Related]
39. mTOR signaling in lymphangioleiomyomatosis.
Kristof AS
Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
[TBL] [Abstract][Full Text] [Related]
40. Emerging biomarkers of lymphangioleiomyomatosis.
Nijmeh J; El-Chemaly S; Henske EP
Expert Rev Respir Med; 2018 Feb; 12(2):95-102. PubMed ID: 29171770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
